On the public citation graph
The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial
0 signed · 58 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.294.14.1799openalex-snapshot
Plasma Fibrinogen Level and the Risk of Major Cardiovascular Diseases and Nonvascular Mortality
inferredcites →https://doi.org/10.1007/s40256-014-0063-6openalex-snapshot
Therapeutic Potential of p38 MAP Kinase Inhibition in the Management of Cardiovascular Disease
inferredcites →https://doi.org/10.1016/j.artres.2011.01.001openalex-snapshot
Aortic calcification, arterial stiffness and bone mineral density in patients with COPD☆
inferredcites →https://doi.org/10.1016/j.artres.2013.10.380openalex-snapshot
Evaluation of losmapimod in patients with chronic obstructive pulmonary disease (COPD) with systemic inflammation stratified using fibrinogen (‘EVOLUTION’): Rationale and protocol
inferredcites →https://doi.org/10.1016/j.blre.2011.05.001openalex-snapshot
Fibrinogen and cardiovascular disease: Genetics and biomarkers
inferredcites →https://doi.org/10.1016/j.jacc.2007.05.024openalex-snapshot
18Fluorodeoxyglucose Positron Emission Tomography Imaging of Atherosclerotic Plaque Inflammation Is Highly Reproducible
inferredcites →https://doi.org/10.1016/j.jacc.2013.04.066openalex-snapshot
Intensification of Statin Therapy Results in a Rapid Reduction in Atherosclerotic Inflammation
inferredcites →https://doi.org/10.1016/j.jcmg.2012.02.016openalex-snapshot
Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis
inferredcites →https://doi.org/10.1016/j.jcmg.2013.08.006openalex-snapshot
Measurement of Arterial Activity on Routine FDG PET/CT Images Improves Prediction of Risk of Future CV Events
inferredcites →https://doi.org/10.1016/s0140-6736(14)60417-7openalex-snapshot
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial
inferredcites →https://doi.org/10.1016/s0735-1097(01)01746-6openalex-snapshot
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery
inferredcites →https://doi.org/10.1016/s2213-2600(13)70200-5openalex-snapshot
Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial
inferredcites →https://doi.org/10.1093/eurheartj/16.suppl_a.6openalex-snapshot
Biochemistry and Measurement of Fibrinogen
inferredcites →https://doi.org/10.1097/00004872-199816121-00033openalex-snapshot
Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis
inferredcites →https://doi.org/10.1136/thoraxjnl-2012-201871openalex-snapshot
Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease: Table 1
inferredcites →https://doi.org/10.1136/thoraxjnl-2013-203498openalex-snapshot
P38 inhibition in COPD; cautious optimism
inferredcites →https://doi.org/10.1161/circ.132.suppl_3.18188openalex-snapshot
Abstract 18188: Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin Deficiency (A1ATD) are Associated With Increased Aortic Inflammation and Stiffness
inferredcites →https://doi.org/10.1161/circulationaha.107.697045openalex-snapshot
Prognostic Significance of Brachial Flow-Mediated Vasodilation
inferredcites →https://doi.org/10.1161/circulationaha.110.971986openalex-snapshot
Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide–Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia
inferredcites →https://doi.org/10.1161/circulationaha.112.120410openalex-snapshot
Anti-Tumor Necrosis Factor-α Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis
inferredcites →https://doi.org/10.1164/ajrccm.164.6.2010067openalex-snapshot
Elevated Plasma Fibrinogen Associated with Reduced Pulmonary Function and Increased Risk of Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1164/rccm.200709-1412ocopenalex-snapshot
Determinants of Systemic Vascular Function in Patients with Stable Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1164/rccm.201101-0021ocopenalex-snapshot
Clinical and Radiographic Predictors of GOLD–Unclassified Smokers in the COPDGene Study
inferredcites →https://doi.org/10.1164/rccm.201509-1722ppopenalex-snapshot
Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease: Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium
inferredcites →https://doi.org/10.1177/0091270010397050openalex-snapshot
An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1183/09031936.00128008openalex-snapshot
Systemic manifestations and comorbidities of COPD
inferredcites →https://doi.org/10.1378/chest.09-2029openalex-snapshot
Increased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPD
inferredcites →https://doi.org/10.1513/pats.200404-032msopenalex-snapshot
Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Morbidity and Mortality
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4100272openalex-extracted
Safety and Efficacy of p38 MAPKI in COPD: A Systematic Review
inferred← citeshttps://doi.org/10.1002/mog2.53openalex-snapshot
p38 mitogen‐activated protein kinase: Functions and targeted therapy in diseases
inferred← citeshttps://doi.org/10.1016/bs.apha.2023.04.004openalex-snapshot
Progress in the development of kinase inhibitors for treating asthma and COPD
inferred← citeshttps://doi.org/10.1016/j.bcp.2024.116307openalex-snapshot
The interplay of p38 MAPK signaling and mitochondrial metabolism, a dynamic target in cancer and pathological contexts
inferred← citeshttps://doi.org/10.1016/j.biopha.2019.01.052openalex-snapshot
New pre-clinical evidence of anti-inflammatory effect and safety of a substituted fluorophenyl imidazole
inferred← citeshttps://doi.org/10.1016/j.coph.2020.03.005openalex-snapshot
Kinase inhibitors in the treatment of obstructive pulmonary diseases
inferred← citeshttps://doi.org/10.1016/j.jns.2024.123096openalex-snapshot
An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1
inferred← citeshttps://doi.org/10.1016/j.nmd.2025.105422openalex-snapshot
The recent clinical trial of losmapimod for the treatment of facioscapulohumeral muscular dystrophy
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2020.107745openalex-snapshot
Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2022.108153openalex-snapshot
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?
inferred← citeshttps://doi.org/10.1038/s41598-020-65374-6openalex-snapshot
Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma
inferred← citeshttps://doi.org/10.1080/15412555.2018.1476475openalex-snapshot
Neutrophilic Inflammation in the Pathogenesis of Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1080/17476348.2020.1735365openalex-snapshot
Clinical relevance of understanding mitogen-activated protein kinases involved in asthma
inferred← citeshttps://doi.org/10.1080/17476348.2021.1919089openalex-snapshot
Vascular endothelial damage in COPD: current functional assessment methods and future perspectives
inferred← citeshttps://doi.org/10.1080/17476348.2023.2176845openalex-snapshot
Endothelial function in patients with COPD: an updated systematic review of studies using flow-mediated dilatation
inferred← citeshttps://doi.org/10.1093/cvr/cvaa211openalex-snapshot
Inflammation and cardiovascular diseases: lessons from seminal clinical trials
inferred← citeshttps://doi.org/10.1124/jpet.119.259663openalex-snapshot
Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy
inferred← citeshttps://doi.org/10.1172/jci.insight.149915openalex-snapshot
p38 MAPKs — roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets
inferred← citeshttps://doi.org/10.1183/16000617.0041-2021openalex-snapshot
Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care
inferred← citeshttps://doi.org/10.1186/s12931-018-0792-1openalex-snapshot
Vascular inflammation and aortic stiffness: potential mechanisms of increased vascular risk in chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1186/s12964-023-01337-4openalex-snapshot
p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics
inferred← citeshttps://doi.org/10.1186/s40658-019-0265-8openalex-snapshot
Reproducibility of compartmental modelling of 18F-FDG PET/CT to evaluate lung inflammation
inferred← citeshttps://doi.org/10.2174/1573406416666200227122849openalex-snapshot
Current Insights of Inhibitors of p38 Mitogen-Activated Protein Kinase in Inflammation
inferred← citeshttps://doi.org/10.31435/ijitss.3(51).2026.6210openalex-snapshot
IN SEARCH OF NOVEL PHARMACOLOGICAL THERAPIES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1684307openalex-snapshot
POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study
inferred← citeshttps://doi.org/10.3389/fphar.2022.950035openalex-snapshot
Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD
inferred← citeshttps://doi.org/10.3390/pathogens13121033openalex-snapshot
Differential TLR-ERK1/2 Activity Promotes Viral ssRNA and dsRNA Mimic-Induced Dysregulated Immunity in Macrophages
inferred← citeshttps://doi.org/10.3390/pharmaceutics13020177openalex-snapshot
Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects
inferred← citeshttps://doi.org/10.3390/v13061156openalex-snapshot
Inhibition of p38 Mitogen-Activated Protein Kinase Impairs Mayaro Virus Replication in Human Dermal Fibroblasts and HeLa Cells
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.